Incyte(INCY) - 2023 Q1 - Earnings Call Presentation

23 xx 1Development of INCB33890 in collaboration with Merus. 25 1Source: Source: Wave 2 ATU fielded February 3 – March 2 Monjuvi sales up 11% Y/Y; continued growth in Community accounts (75% of total volume) Opzelura launch has outperformed other brands prescribed by dermatologists Atopic dermatitis and vitiligo patient relationship and support programs to help patients start and stay on therapy Treatment of choice in CCA and MLN for eligible patients in the U.S. Pemazyre launch is ongoing in 10 key markets ...